Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapy
Joost L. Boormans(Erasmus MC), Yair Lotan(Southwestern Medical Center), Jean L. Wright(University of North Carolina at Chapel Hill), Tarek A. Bismar(University of Calgary), Elai Davicioni(Coherus BioSciences (United States)), Ewan A. Gibb(BC Cancer Agency), Joep J. de Jong(Erasmus MC Cancer Institute), Hristos Z. Kaimakliotis(Indiana University Health), Stephen A. Boorjian(Mayo Clinic), Marc Dall’Era(University of California, Davis), Andrea Necchi(Vita-Salute San Raffaele University), H-C. Huang, Omar Y. Mian(Fred Hutch Cancer Center), P. Black, V.Y.T. Liu
Cited by 1
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
|Cancer Cell|2017|2.1k